Evommune, Inc. (NYSE:EVMN) Stock Has Average Target Price of $30.80

Evommune, Inc. (NYSE:EVMN) has earned an average rating of “Moderate Buy” from the sixteen research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $30.80.

A number of analysts have commented on EVMN shares. Leerink Partners cut their price target on shares of Evommune from $28.00 to $22.00 and set an “outperform” rating for the company in a research note on Wednesday, September 9th. Stifel Nicolaus set a $30.00 price objective on shares of Evommune in a research note on Wednesday, September 9th. Raymond James Financial set a $18.00 target price on shares of Evommune in a report on Wednesday, September 9th. Needham & Company LLC began coverage on shares of Evommune in a research note on Wednesday, August 26th. They issued a “buy” rating and a $28.00 target price for the company. Finally, Weiss Ratings downgraded shares of Evommune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 11th.

Hedge Funds Weigh In On Evommune

A number of large investors have recently made changes to their positions in the company. Janus Henderson Group PLC bought a new position in Evommune during the 1st quarter worth $20,615,000. Stempoint Capital LP raised its holdings in Evommune by 184.1% in the 1st quarter. Stempoint Capital LP now owns 193,777 shares of the company’s stock valued at $4,385,000 after acquiring an additional 125,581 shares in the last quarter. Perceptive Advisors LLC bought a new stake in shares of Evommune during the 1st quarter valued at $10,308,000. Defilade Capital Management L.P. lifted its position in shares of Evommune by 215.0% during the 1st quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock valued at $15,601,000 after acquiring an additional 463,171 shares during the period. Finally, Eversept Partners LP acquired a new stake in shares of Evommune during the 1st quarter worth $1,257,000.

Evommune Stock Down 4.1%

NYSE EVMN opened at $5.16 on Thursday. The firm’s 50 day moving average is $9.92 and its 200-day moving average is $16.16. The company has a market capitalization of $187.33 million and a PE ratio of -0.47. Evommune has a 12-month low of $5.09 and a 12-month high of $33.20.

Evommune (NYSE:EVMN) last released its earnings results on Thursday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.21). As a group, sell-side analysts expect that Evommune will post -3.29 EPS for the current year.

Evommune Company Profile

Evommune, Inc is a clinical-stage biotechnology company focused on developing new treatments for immune-mediated inflammatory diseases. The company’s research is centered on identifying therapies that address the underlying biological mechanisms driving chronic inflammation rather than primarily treating symptoms.

Evommune is advancing a pipeline of investigational medicines designed for conditions with significant unmet medical needs, including dermatologic and other inflammatory disorders.